260 related articles for article (PubMed ID: 21170268)
1. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma.
Kannan N; Kang J; Kong X; Tang J; Perry JK; Mohankumar KM; Miller LD; Liu ET; Mertani HC; Zhu T; Grandison PM; Liu DX; Lobie PE
Neoplasia; 2010 Dec; 12(12):1041-53. PubMed ID: 21170268
[TBL] [Abstract][Full Text] [Related]
2. Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma.
Kang J; Qian PX; Pandey V; Perry JK; Miller LD; Liu ET; Zhu T; Liu DX; Lobie PE
Oncogene; 2010 Jun; 29(22):3228-40. PubMed ID: 20305694
[TBL] [Abstract][Full Text] [Related]
3. Trefoil Factor-3 (TFF3) Stimulates De Novo Angiogenesis in Mammary Carcinoma both Directly and Indirectly via IL-8/CXCR2.
Lau WH; Pandey V; Kong X; Wang XN; Wu Z; Zhu T; Lobie PE
PLoS One; 2015; 10(11):e0141947. PubMed ID: 26559818
[TBL] [Abstract][Full Text] [Related]
4. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
5. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ
Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379
[TBL] [Abstract][Full Text] [Related]
6. Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma.
Pandey V; Wu ZS; Zhang M; Li R; Zhang J; Zhu T; Lobie PE
Breast Cancer Res; 2014 Sep; 16(5):429. PubMed ID: 25266665
[TBL] [Abstract][Full Text] [Related]
7. ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma.
Banerjee A; Wu ZS; Qian P; Kang J; Pandey V; Liu DX; Zhu T; Lobie PE
Breast Cancer Res; 2011; 13(6):R112. PubMed ID: 22060274
[TBL] [Abstract][Full Text] [Related]
8. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
Habashy HO; Powe DG; Staka CM; Rakha EA; Ball G; Green AR; Aleskandarany M; Paish EC; Douglas Macmillan R; Nicholson RI; Ellis IO; Gee JM
Breast Cancer Res Treat; 2010 Jan; 119(2):283-93. PubMed ID: 19238537
[TBL] [Abstract][Full Text] [Related]
9. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
[TBL] [Abstract][Full Text] [Related]
10. A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro.
Kurebayashi J; Otsuki T; Yamamoto S; Kurosumi M; Nakata T; Akinaga S; Sonoo H
Oncology; 1998 Dec; 55 Suppl 1():23-34. PubMed ID: 9852399
[TBL] [Abstract][Full Text] [Related]
11. Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.
Taylor KJ; Sims AH; Liang L; Faratian D; Muir M; Walker G; Kuske B; Dixon JM; Cameron DA; Harrison DJ; Langdon SP
Breast Cancer Res; 2010; 12(3):R39. PubMed ID: 20569502
[TBL] [Abstract][Full Text] [Related]
12. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
[TBL] [Abstract][Full Text] [Related]
13. Small molecule inhibition of TFF3 overcomes tamoxifen resistance and enhances taxane efficacy in ER+ mammary carcinoma.
Guo H; Tan YQ; Huang X; Zhang S; Basappa B; Zhu T; Pandey V; Lobie PE
Cancer Lett; 2023 Nov; 579():216443. PubMed ID: 37858772
[TBL] [Abstract][Full Text] [Related]
14. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
Fernandez-Cuesta L; Anaganti S; Hainaut P; Olivier M
Int J Cancer; 2011 Apr; 128(8):1813-21. PubMed ID: 20549698
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.
Ishii Y; Papa L; Bahadur U; Yue Z; Aguirre-Ghiso J; Shioda T; Waxman S; Germain D
Clin Cancer Res; 2011 Apr; 17(8):2292-300. PubMed ID: 21292820
[TBL] [Abstract][Full Text] [Related]
16. The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.
Ikeda H; Taira N; Hara F; Fujita T; Yamamoto H; Soh J; Toyooka S; Nogami T; Shien T; Doihara H; Miyoshi S
Breast Cancer Res; 2010; 12(3):R43. PubMed ID: 20579400
[TBL] [Abstract][Full Text] [Related]
17. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.
You ML; Chen YJ; Chong QY; Wu MM; Pandey V; Chen RM; Liu L; Ma L; Wu ZS; Zhu T; Lobie PE
Oncotarget; 2017 Jun; 8(24):39323-39344. PubMed ID: 28445151
[TBL] [Abstract][Full Text] [Related]
18. Trefoil factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells.
Amiry N; Kong X; Muniraj N; Kannan N; Grandison PM; Lin J; Yang Y; Vouyovitch CM; Borges S; Perry JK; Mertani HC; Zhu T; Liu D; Lobie PE
Endocrinology; 2009 Oct; 150(10):4473-83. PubMed ID: 19589871
[TBL] [Abstract][Full Text] [Related]
19. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.
Cottu P; Bièche I; Assayag F; El Botty R; Chateau-Joubert S; Thuleau A; Bagarre T; Albaud B; Rapinat A; Gentien D; de la Grange P; Sibut V; Vacher S; Hatem R; Servely JL; Fontaine JJ; Decaudin D; Pierga JY; Roman-Roman S; Marangoni E
Clin Cancer Res; 2014 Aug; 20(16):4314-25. PubMed ID: 24947930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
